Recent Updates
Recently added Catalysts

Refractory Diffuse Large B-Cell Lymphoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.5Buniverse median $1.20B
Allocated capital$410M$2.5B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank226/299crowding rank 229

Refractory Diffuse Large B-Cell Lymphoma is uncontested. HUTCHMED (China) (HCM) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with R-GemOx in phase 3.

There is no public comparable to price it against. HCM spreads its $2.5B market cap across 6 indications, so $410M of it is allocated here.

The one programme here is in late-stage development, but it carries no dated catalyst in the next 12 months.

$410M of allocated capital sits in Refractory Diffuse Large B-Cell Lymphoma, ranking it 226th of 299 indications by the money committed to it.

Companies developing drugs for Refractory Diffuse Large B-Cell Lymphoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
HCMHUTCHMED (China)R-GemOxPhase 35$2.5BNo6No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Refractory Diffuse Large B-Cell Lymphoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Refractory Diffuse Large B-Cell Lymphoma has one competitor and a median of $2.5B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Advanced Endometrial Cancer1 company · $410M · median $2.5BUncontestedT-cell Lymphoma1 company · $411M · median $1.2BUncontestedPeripheral T-cell Lymphoma1 company · $411M · median $1.2BUncontestedMultiple Myeloma3 companies · $421M · median $460MOrphan cornerChoroidal Melanoma1 company · $382M · median $764MUncontestedTriple Negative Metastatic Breast Cancer1 company · $448M · median $1.8BUncontestedEwing Sarcoma1 company · $448M · median $1.8BUncontestedChondrosarcoma1 company · $448M · median $1.8BUncontested

Refractory Diffuse Large B-Cell Lymphoma pipeline questions

Which biotech companies are developing drugs for Refractory Diffuse Large B-Cell Lymphoma?

HUTCHMED (China) (HCM, R-GemOx, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Refractory Diffuse Large B-Cell Lymphoma.

How advanced is the Refractory Diffuse Large B-Cell Lymphoma pipeline?

Of the 1 clinical-stage programme in Refractory Diffuse Large B-Cell Lymphoma, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Refractory Diffuse Large B-Cell Lymphoma?

No. HCM is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Refractory Diffuse Large B-Cell Lymphoma, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map